Annals of Surgical Oncology Sign the Guestbook
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Alves, A.
Right arrow Articles by Bismuth, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Alves, A.
Right arrow Articles by Bismuth, H.
Related Collections
Right arrow Surgery
Annals of Surgical Oncology 10:705-710 (2003)
© 2003 Society of Surgical Oncology


ORIGINAL ARTICLES

Hepatic Resection for Metastatic Renal Tumors: Is It Worthwhile?

A. Alves, MD, R. Adam, MD, PhD, P. Majno, MD, PhD, V. Delvart, Biostatistician, D. Azoulay, MD, PhD, D. Castaing, MD and H. Bismuth, MD, FACS

From the Centre Hépato-Biliaire, Hôpital Paul Brousse, Université Paris-Sud, Villejuif, France.

Correspondence: Address correspondence and reprint requests to: René Adam, MD, PhD, Centre Hépato-Biliaire, Hôpital Paul Brousse, Université Paris-Sud 94804, Villejuif, France; Fax: 33-01-45-59-38-57; E-mail: rene.adam{at}pbr.ap-hop-paris.fr

Background: Liver metastases of malignant renal tumors are regarded as having an ominous prognosis because they are infrequently amenable to radical surgery and respond poorly to chemotherapy. Little is known of the outcome of isolated metastases to the liver for which resection is potentially curative.

Methods: Data on 14 patients with liver metastases from renal tumors who underwent a liver resection in a single center between 1982 and 2001 were analyzed retrospectively.

Results: There was no operative or postoperative mortality. The median survival was 26 months, with a survival rate of 69% at 1 year and 26% at 3 years. The curative pattern of hepatectomy (2-year survival, 69% vs. 0%; P = .001), an interval between the nephrectomy and the diagnosis of liver metastases in excess of 24 months (2-year survival, 71% vs. 25%; P = .05), tumor size <50 mm (2-year survival, 83% vs. 17%; P = .006), and the possibility of achieving a repeat hepatectomy in the case of recurrence (2-year survival, 100% vs. 21%; P = .02) were associated with a better outcome after the liver resection. Four patients were alive without evidence of disease at 6, 12, 26, and 96 months after the first hepatic resection, and one was alive with hepatic recurrence 18 months after resection.

Conclusions: In patients with liver metastases of malignant renal tumors, an aggressive policy for achieving tumor eradication seems to offer a chance for long-term survival, especially after a long disease-free interval from the nephrectomy. However, despite an aggressive policy for achieving tumor eradication, recurrence frequently occurs after liver resection.

Key Words: Liver metastases • Renal tumor • Hepatic resection • Prognosis







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the Society of Surgical Oncology.